Watch the CEO Signature Series interview with Robert G. Finizio, CEO, Founder and Director of TherapeuticsMD (TXMD).
Biography:
Robert G. Finizio is a Chief Executive Officer, Co-Founder, and Director of TherapeuticsMD. Mr. Finizio has 20 years of medical knowledge and co-founded TherapeuticsMD in 2008, leveraging his entrepreneurial and remedy record credentials into women’s health. Utilizing a Company’s exclusive technologies, Mr. Finizio is heading TherapeuticsMD by a clinical growth and regulatory examination for novel hormone therapy products, targeting large, unmet marketplace needs associated to menopause government globally. In his stream role, Mr. Finizio has lifted some-more than $250 million in collateral for a company. Mr. Finizio is a connoisseur of a University of Miami and taught English in Osaka, Japan before rising his medical career, operative in a Operating Room for Endoscopy Specialist Incorporated (ESI) in Operational, Sales, and Regional Management roles. After ESI, Mr. Finizio assimilated OmniCell Technologies a personality in remedy management. In 2001, Mr. Finizio co-founded remedy and clinical record businessman CareFusion, offered it to Cardinal Health in 2006.
Company Description:
TherapeuticsMD, Inc. is an innovative medical association focused on building and commercializing products exclusively for women. With a SYMBODA™ technology, TherapeuticsMD is building modernized hormone therapy curative products to capacitate smoothness of bio-identical hormones by a accumulation of dose forms and administration routes. The Company’s late theatre clinical tube includes dual proviso 3 product candidates: TX-001HR for diagnosis of moderate-to-severe vasomotor symptoms (VMS) due to menopause and TX-004HR for diagnosis of moderate-to-severe vaginal pain during passionate retort (dyspareunia), a sign of vulvar and vaginal atrophy (VVA) due to menopause. The Company also manufactures and distributes branded and general medication prenatal vitamins underneath a vitaMedMD® and BocaGreenMD® brands.